



December 17, 2024

To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra – Kurla Complex Bandra (East) <u>Mumbai – 400 051</u> Stock Code: INDOCO-EQ	To The Listing Department Bombay Stock Exchange Limited Floor 25, P. J. Towers, Dalal Street, <u>Mumbai – 400 001</u> Stock Code: 532612
---	--

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is further to our notification dated October 11, 2024, for receipt of Official Action Indicated (OAI) status from the USFDA for Plant II & Plant III facility located at L 32, 33 - 34 Verna Industrial Estate Area, Verna, Goa, India ("Facility"). Subsequently, the Facility has received a warning letter from the USFDA on December 17, 2024. This Facility was inspected from July 16, 2024 to July 26, 2024.

The Company remains committed to work closely with the USFDA and continues to enhance its compliance on an ongoing basis. We will work with the USFDA to resolve these issues at the earliest. We uphold quality and compliance issues with utmost importance and remain committed to be compliant with CGMP quality standards across our facilities.

We continue to supply products from the above-mentioned Facility to meet our obligations to our customers and the patients in the United States of America.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above is for your information and dissemination.

**Thanking you,
Yours faithfully,
For Indoco Remedies Limited**

**Ramanathan Hariharan
Company Secretary & Head-Legal**

